Differenzialindikation von Antidepressiva

Lernziele

Ziel dieses Artikels ist es, Vor- und Nachteile verschiedener Antidepressiva auf Grundlage komplexer Behandlungssituationen wie komorbiden Erkrankungen und pharmakologischen Besonderheiten über normales Lehrbuchwissen hinaus zu identifizieren. Damit sollen individualisierte Therapiestrategien aufgezeigt werden, die evtl. Vorteile gegenüber der Standardbehandlung haben. Diese beinhalten eine individualisierte Monotherapie, pharmakologisch sinnvolle Kombinationstherapien und adjuvante Behandlungsoptionen.

• Literatur

• 1 Kaptchuk TJ. The double-blind, randomized, placebo-controlled trial: gold standard or golden calf?. J Clin Epidemiol 2001; 54: 541-549
• 2 DGPPN, BÄK, KBV et al. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression-Langfassung. 23.09.2010 cited 2009 Available from: www.dgppn.de, www.versorgungsleitlinien.de, www.awmf-leitlinien.de
• 3 Härter M, Klesse C, Bermejo I et al. Unipolar depression: diagnostic and therapeutic recommendations from the current S3/National Clinical Practice Guideline. Dtsch Arztebl Int 2010; 107: 700-708
• 4 Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-758
• 5 Turner E, Moreno SG, Sutton AJ. Ranking antidepressants. Lancet 2009; 373: 1760 ; author reply 1761–1762
• 6 Nelson JC, Portera L, Leon AC. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine. J Clin Psychiatry 2005; 66: 1409-1414
• 7 Benkert O, Hippius H. Antidepressiva, in Kompendium der Psychiatrischen Pharmakotherapie. Heidelberg: Springer; 2011: 1-132
• 8 Lotufo-Neto F, Bernik M, Ramos RT et al. A dose-finding and discontinuation study of clomipramine in panic disorder. J Psychopharmacol 2001; 15: 13-17
• 9 Mavissakalian MR. Imipramine vs. sertraline in panic disorder: 24-week treatment completers. Ann Clin Psychiatry 2003; 15: 171-180
• 10 Davidson JR, Foa EB, Huppert JD et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 2004; 61: 1005-1013
• 11 Albert U, Aguglia E, Maina G et al. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry 2002; 63: 1004-1009
• 12 Bloch MH, McGuire J, Landeros-Weisenberger A et al. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry 2010; 15: 850-855
• 13 Bisson JI. Post-traumatic stress disorder. Clin Evid 2010; (Online)
• 14 Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev 2009; 4: CD007115
• 15 Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007; 4: CD005454
• 16 Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 2010; 71: 754-763
• 17 O’Brien S, Rapkin A, Dennerstein L et al. Diagnosis and management of premenstrual disorders. BMJ 2011; 342: d2994
• 18 Raupach T, van Schayck CP. Pharmacotherapy for smoking cessation: current advances and research topics. CNS Drugs 2011; 25: 371-382
• 19 Sidor MM, Macqueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry 2011; 72: 156-167
• 20 Thase ME. Pharmacotherapy of bipolar depression: an update. Curr Psychiatry Rep 2006; 8: 478-488
• 21 Spina E, Scordo MG. Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 2002; 19: 299-320
• 22 Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int 2011; 108: 687-693
• 23 Cobos EJ, Entrena JM, Nieto FR et al. Pharmacology and therapeutic potential of sigma (1) receptor ligands. Curr Neuropharmacol 2008; 6: 344-366
• 24 Sadock BJ, Sadock VA. Behavioral Sciences/Clinical Psychiatry. In: Kaplan and Sadock’s Synopsis of Psychiatry. Philadelphia: Lippincott Williams and Wilkins; 2007: 977-1126
• 25 Tang SW, Helmeste D. Paroxetine. Expert Opin Pharmacother 2008; 9: 787-794
• 26 Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010; 71: 1259-1272
• 27 Bobo WV, Shelton RC. Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data. Expert Opin Pharmacother 2009; 10: 2145-2159
• 28 Bellani M, Dusi N, Yeh PH et al. The effects of antidepressants on human brain as detected by imaging studies. Focus on major depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1544-1552
• 29 Brunello N, Mendlewicz J, Kasper S et al. The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur Neuropsychopharmacol 2002; 12: 461-475
• 30 Thase ME, Shelton RC, Khan A. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J Clin Psychopharmacol 2006; 26: 250-258
• 31 Müller N, Schennach R, Riedel M et al. Duloxetine in the treatment of major psychiatric and neuropathic disorders. Expert Rev Neurother 2008; 8: 527-536
• 32 Benjamin S, Doraiswamy PM. Review of the use of mirtazapine in the treatment of depression. Expert Opin Pharmacother 2011; 12: 1623-1632
• 33 Dhillon S, Yang LP, Curran MP. Bupropion: a review of its use in the management of major depressive disorder. Drugs 2008; 68: 653-689
• 34 Javelot T, Javelot H, Baratta A et al. Acute psychotic disorders related to bupropion: review of the literature. Encephale 2010; 36: 461-471
• 35 Moreira R. The efficacy and tolerability of bupropion in the treatment of major depressive disorder. Clin Drug Investig 2011; 31 (Suppl. 01) 5-17
• 36 Hewett K, Gee MD, Krishen A et al. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol 2010; 24: 1209-1216
• 37 Singh SP, Singh V, Kar N. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int J Neuropsychopharmacol 2011; epub ahead of print
• 38 De Berardis D, Di Iorio G, Acciavatti T et al. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurol Disord Drug Targets 2011; 10: 119-132
• 39 Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58: 19-36
• 40 Adli M, Baethge C, Heinz A et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005; 255: 387-400
• 41 Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr 2008; 13: 855-870
• 42 Ben-Arie O, George GC. A case of tranylcypromine (“Parnate”) addiction. Br J Psychiatry 1979; 135: 273-274
• 43 Fava M, Rush AJ, Trivedi MH et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am 2003; 26: 457-494
• 44 Köhler S, Bauer M, Adli M. Behandlungsstrategien der therapieresistenten Depression. Psychiatrie und Psychotherapie up2date 2012; 6: 137-148
• 45 Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905-1917
• 46 Köhler S. Vergleich medikamentöser Behandlungsstrategien bei Patienten mit unipolarer Depression und primärem Therapieversagen in einem stationären Setting. Dresden: Medizinische Fakultät der Technischen Universität Carl Gustav Carus; 2011: 150
• 47 Bschor T, Baethge C. No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy. Acta Psychiatr Scand 2010; 121: 174-179
• 48 Souery D, Serretti A, Calati R et al. Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study. World J Biol Psychiatry 2011; 12: 364-375
• 49 Blier P, Gobbi G, Turcotte JE et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 2009; 19: 457-465
• 50 Blier P, Ward HE, Tremblay P et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010; 167: 281-288
• 51 Trivedi MH, Fava M, Wisniewski SR et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354: 1243-1252
• 52 Rush AJ, Trivedi MH, Stewart JW et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011; 168: 689-701